ArticleMedicine2025
Model development and validation for predicting small-cell lung cancer bone metastasis utilizing diverse machine learning algorithms based on the SEER database.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aim of this study was to devise a machine learning algorithm with superior performance in predicting bone metastasis (BM) in small cell lung cancer (SCLC) and create a straightforward web-based predictor based on the developed algorithm. Data comprising demographic and clinicopathological characteristics of patients with SCLC and their potential BM were extracted from the Surveillance, Epidemiology, and End Results database between 2010 and 2018. This data was then utilized to develop 12 machine learning algorithm models: support vector machine, logistic regression, NaiveBayes, extreme gradient boosting, decision tree, random forest, ExtraTrees, LightGBM, GradientBoosting, AdaBoost, MLP, and k-nearest neighbor. The models were compared and evaluated using various metrics, including accuracy, precision, recall rate, F1-score, the area under the receiver operating characteristic curve (AUC) value, and the Brier score. The objective was to predict the likelihood of BM in SCLC patients based on their demographic and clinicopathological features. The best-performing model was then chosen, and the associations between the clinicopathological characteristics and the target variable (presence or absence of BM) were interpreted based on this model. This analysis aimed to provide insights into the factors that may influence the risk of BM in SCLC patients. A total of 89,366 SCLC patients were included in this study, and among them, 8269 (9.25%) patients developed BM. The age, T stage, N stage, liver metastasis, lung metastasis, marital status, income, M stage, American Joint Committee on Cancer stage, and brain metastasis were identified as independent risk factors for SCLC. Among the various predictive models evaluated, the machine learning model utilizing the XGB algorithm showed the highest performance in both internal and external data validation, achieving AUC scores of training set AUC: 0.965, validation set AUC: 0.962, and testing set AUC: 0.961. Subsequently, the XGB algorithm was utilized to develop a web-based predictor for BM in patients with SCLC. This study has developed a web-based predictor utilizing the XGB algorithm to forecast the risk of BM in SCLC patients, aiming to provide doctors with valuable assistance in clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.